Biotech Company profiles at provigator.com |  Email This Post | View all Company profiles for Biotech 448 views

Established in 1978, Biocon is India’s premier biotechnology company. Headquartered in Bangalore Biocon has evolved from an enzyme company to a fully integrated biopharmaceutical enterprise, focused on healthcare. In 2007, Biocon made a strategic decision to divest its historic enzymes business to Novozymes A/S of Denmark. Biocon now strategically focuses its activities on its bio-pharma business verticals that include APIs, biologicals and proprietary molecules both commercialized and under development with this divestment, the company mission is to ‘Develop novel & affordable Biotherapeutics for global markets’.

Biocon Limited and its two subsidiary companies, Syngene International Limited and Clinigene International Limited form a fully integrated biotechnology enterprise specializing in biopharmaceuticals, custom research and clinical research. Biocon’s integrated business approach has enabled the company to establish a significant presence in the global biopharmaceutical market via its product offerings and customised, high value solutions at any stage in the lifecycle of a drug-from discovery to market. Biocon’s vision is to be an integrated biopharmaceutical enterprise of global distinction.

The company applies its proprietary fermentation technologies to make effective and innovative biomolecules in diabetology, oncology, cardiology and other therapeutic segments. Biocon’s products in the biopharmaceutical category include: anti-diabetic agents, anti-hypertensive agents, anti-inflammatory agents, anti-oxidants, biologicals, cholesterol-lowering agents, haemostatic agents, hepatoprotective agents,
immunosuppressants, nutraceuticals and orthopaedic agents.

With its strong focus on R&D Biocon offers services in custom research (Syngene) in the fields of synthetic chemistry and molecular biology in early stage drug discovery and development. Clinical research (Clinigene) is carried out in the fields of clinical studies and clinical trials.

Biocon Park, inaugurated in June 2006 by President APJ Abdul Kalam comprises an integrated cluster of research laboratories and manufacturing facilities laid out on a 90 acre expanse in Bommasandra Industrial Area – Phase IV. Built with a total investment of Rs. 650 crores, with further investments to follow, Biocon Park is the single largest capital investment made by Biocon in its 32-year history and is focused on exports of both bio-pharmaceutical products and research services. The multi-product facilities mainly cater to the following disease segments: cardiovascular, cholesterol reduction, immunosuppressants in organ transplantation, diabetes and cancer.

Biocon’s success has been characterized by an enduring set of corporate values based on innovation, integrity, strong leadership and social responsibility. As India’s first and leading biotechnology company Biocon extends its support to numerous community outreach and corporate citizenship initiatives with special concentration in the areas of healthcare, education and environment. The Biocon Foundation, set up in 2004 has launched Arogya Raksha Yojana, a unique health initiative for rural India.

Biocon aims to continuously create growth in different areas of the company and is the first company, globally to manufacture human insulin, Insugen® using a Pichia expression system. In addition, in 2006, Biocon launched BIOMAb EGFR™, the first indigenously developed humanized monoclonal antibody for Head & Neck cancer.

Key Facts:

• Biocon is India’s first biotechnology company, established in 1978
• Biocon is the country’s first biotechnology company to export microbial enzymes to USA and Europe
• Biocon is the first biotechnology company to receive ISO 9001 certification in India
• Syngene, a Biocon subsidiary, is the country’s first biotech custom research company in drug discovery
• Biocon is the first Indian company to be approved by US FDA for the manufacture of pplovastatin, a cholesterol-lowering molecule
• Biocon’s subsidiary, Clinigene, has India’s first CAP (College of American Pathologists) accredited clinical research laboratory
• Biocon is the first company to manufacture human insulin using a Pichia expression system

Businesses:

Syngene: Pre-Clinical Discovery
Biocon’s custom research organisation, Syngene, offers high value discovery and development services, from target identification and validation to small molecule and library synthesis. With our reputation for meticulous IPR protection, we provide pharmaceutical and biotechnology majors customised solutions in the areas of synthetic chemistry and molecular biology.

Clinigene: Clinical Development
Biocon’s clinical research organisation, Clinigene, specialises in Phase I-IV clinical trials and studies, using well-characterised clinical databases in diabetes, oncology, lipidemia and cardiovascular diseases. We offer these services at our CAP and NABL accredited Central Reference Laboratory and a state-of-the-art Bioavailability and Bioequivalence (BA/BE) Centre.

Biocon: Commercialisation
Biocon has an impressive track record of commercialisation capabilities. We have brought to market a considerable portfolio of biopharmaceuticals, led by our blockbuster Statins. The commercialisation of Insulin, Immunossuppressants and a range of Biogenerics demonstrates our highly advanced process development and manufacturing expertise. Under rapid progress are two challenging collaborative projects for the development of novel medicine, including Oral Insulin and T1h. Biocon also markets a basket of branded formulations in India, among them INSUGEN®, BIOMAb EGFR® and EPO.

Milestones

• Biocon is India’s first biotechnology company, established in 1978
• Biocon is India’s first biotechnology company to export microbial enzymes to USA and Europe
• Biocon is the first biotechnology company to receive ISO 9001 certification in India
• Syngene, a Biocon subsidiary, is India’s first custom research company in drug discovery
• Biocon is the first Indian company to be approved by US FDA for the manufacture of lovastatin, a cholesterol-lowering molecule
• Biocon’s proprietary bioreactor, the PlaFractor™, receives a US patent
• Biocon’s subsidiary, Clinigene, has India’s first CAP (College of American Pathologists) accredited clinical research laboratory, setting the benchmark for laboratories in India
• Biocon is awarded the Biotech Product and Process Development and Commercialisation Award, 2001 by the Department of Biotechnology, Ministry of Science and Technology, Government of India
• Syngene is awarded the Certificate of Excellence for Export Achievement by the Government of India, for two consecutive years 2002-2003
• Biocon is the first company, globally to manufacture human insulin, INSUGEN®, using a Pichia expression system (2004)
• Biocon launches BIOMAb EGFR® India’s first anti-cancer, therapeutic Monoclonal Antibody-based drug for treating solid tumors of epithelial origin, such as head & neck cancers (2006)
• Biocon divests its enzymes division to Novozymes, focuses on biopharmaceuticals (2007)
• Syngene receives “BioServices Company of the Year”, BioSpectrum Awards (2007)
• Biocon’s BIOMAb EGFR® wins “Product of the Year”, BioSpectrum Awards (2007)
• Biocon acquires a 78% stake in German pharmaceutical company, AxiCorp GmbH for a consideration of €30 Million (2008)
• Biocon launches a Safety Device in the form of pre-filled syringes for two of its life saving products, GCSF (granulocyte- colony stimulating factor) and EPO (Erythropoietin) in collaboration with Safety Syringes Inc. ERYPRO Safe™ and NUFIL Safe™ are the first two drugs that will marketed using this novel device with other injectable products to follow in the future (2008)
• Biocon and Abraxis Bioscience launch ABRAXANE in India for treatment of Breast Cancer (2008)
• Biocon is ranked among the top 20 global biotechnology companies (Med Ad News) (2008)
• Biocon is the 7th largest biotech employer in the world (Med Ad News), 2008
• Biocon announced the results of an ascending dose study on its oral insulin drug (IN-105) at the European Association for the Study of Diabetes (EASD) meeting in Rome (2008)
• NeoBiocon and Abraxis Bioscience launch Abraxane in The UAE for the treatment of Breast Cancer (2008)
• Biocon’s Syngene partners with Sapient Discovery to expand integrated drug discovery offerings (2009)
• Biocon’s Syngene and DuPont Crop Protection Forge Alliance Partnership (2009)
• Bristol-Myers Squibb and Biocon’s Syngene open new R&D Facility at Biocon Park (2009)
• Biocon launches BASALOG – long lasting basal insulin for Type 1 & Type 2 Diabetics (2009)
• Biocon inks partnership with ISB to launch the Biocon Cell for Innovation Management (2009)
• Biocon Announces Strategic Collaboration with Mylan to enter the Global Generic Biologics Market (2009)

Products:

Biopharmaceuticals

Active Pharmaceutical Ingredients (APIs)

• Anti-Diabetic Agents
• Anti-Inflammatory Agents
• Anti-Oxidants
• Cardiovascular Agents
• Anti-Obesity Agents
• Digestive-Aid Enzymes
• Anti-Hypertensive Agents
• Haemostatic Agents
• Hepatoprotective Agents
• Immunosuppressants
• Gastro-Intestinal Agents
• Nutraceuticals

Biologicals

• Insulin
• Streptokinase
• EPO
• GCSF
• Monoclonal Antibodies

Branded Formulations

Oncology

• BIOMAb EGFR®
• NUFIL safe™ (Pre-filled Syringe)
• NUFIL™ (Vials)
• Abraxane® for injectable suspension

Nephrology

• ERYPRO safe™ (Pre-filled Syringe)
• TACROGRAF™
• RAPACAN™
• CYCLOPHIL ME™
• RENODAPT®
• RENODAPT® – S
• CeRACaL™

Cardiology

• STATIX®
• STATIX®-F
• STATIX®-EZ
• BESTOR®
• TELMISAT™
• TELMISAT™-H
• ZARGO®
• ZARGO®-H
• ZIGPRIL®
• ACTIBLOK™-IPR
• BRADIA™
• CLASPRIN®
• THINRIN™
• MYOKINASE™
• CLOTIDE™
• DYNALIX®

Diabetology

• INSUGEN®-R
• INSUGEN®-N
• INSUGEN®-30/70
• INSUGEN®-50/50
• BASALOG™ 3ml, 10 ml
• BLISTO™ 1, 2 & 4
• BLISTO™-MF 1, 2 & 4
• METADOZE-IPR® 500 & 850
• PIODART®
• PIODART®-MF
• TriGPM™
• ZUKER™-MF
• GABIL™
• GMAB™ Plus
• OLISAT™

Corporate Headquarters:

20th KM Hosur Road
Electronics City
Bangalore – 560 100
India

Tel: +91-80-28082808/+91-80-40144014
Fax: +91-80-28523423

List of Offices

http://www.biocon.com